Synthesis, crystal structure, Hirshfeld surface analysis, MEP study and mol-ecular docking of -{3-[(4-meth-oxy-phen-yl)carbamo-yl]phen-yl}-3-nitro-benzamide as a promising inhibitor of hfXa.

The title compound, CHNO, consists of three rings, , and , linked by amide bonds with the benzene rings and being inclined to the mean plane of the central benzene ring by 2.99 (18) and 4.57 (18)°, respectively. In the crystal, mol-ecules are linked N-H⋯O and C-H⋯O hydrogen bonds, forming fused (18), (30), (38) rings running along [0] and (37) and (15) rings along [001]. Hirshfeld analysis was undertaken to study the inter-molecular contacts in the crystal, showing that the most significant contacts are H⋯O/O⋯H (30.5%), H⋯C/C⋯H (28.2%) and H⋯H (29.0%). Two zones with positive (50.98 and 42.92 kcal mol) potentials and two zones with negative (-42.22 and -34.63 kcal mol) potentials promote the N-H⋯O inter-actions in the crystal. An evaluation of the mol-ecular coupling of the title compound and the protein with enzymatic properties known as human coagulation factor Xa (hfXa) showed the potential for coupling in three arrangements with a similar minimum binding energy, which differs by approximately 3 kcal mol from the value for the mol-ecule Apixaban, which was used as a positive control inhibitor. This suggests the title compound exhibits inhibitory activity.